Loading…

Anti-dementia medication use in Aotearoa New Zealand: An exploratory study using health data from the Integrated Data Infrastructure (IDI)

Objective: Anti-dementia medications such as acetylcholinesterase inhibitors are an important part of the management pathway for dementia. However, there are limited data in New Zealand that have examined the rates and patterns of use of funded anti-dementia medication and how use differs with ethni...

Full description

Saved in:
Bibliographic Details
Published in:Australian and New Zealand journal of psychiatry 2023-06, Vol.57 (6), p.895-903
Main Authors: Chan, Amy Hai Yan, Hikaka, Jo anna, To, Edith, Cullum, Sarah, Ma’u, Etuini, Ryan, Brigid, Rivera-Rodriguez, Claudia, Cheung, Gary
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Anti-dementia medications such as acetylcholinesterase inhibitors are an important part of the management pathway for dementia. However, there are limited data in New Zealand that have examined the rates and patterns of use of funded anti-dementia medication and how use differs with ethnicity, age and sex. Methods: This was a retrospective population-based descriptive study. Using the Integrated Data Infrastructure, we identified individuals of all ages coded for a diagnosis of dementia and estimated the proportion dispensed funded anti-dementia medication – donepezil tablets and rivastigmine patches – between 1 July 2016 and 30 June 2020. Rates of medication use in five main ethnic groups (Māori, Pacific peoples, Asian, European, and Middle Eastern, Latin American and African) in the
ISSN:0004-8674
1440-1614
1440-1614
DOI:10.1177/00048674221121091